2019 was a busy year for Coalition to Cure Calpain 3! During the past year we: • Funded two new research projects: Funding was awarded to Dr. Jaakko Sarparanta, Folkhälsan Research Center and the University of Helsinki, and Dr. Nicholas
Promising Insights into Safety of LGMD2A/R1 Gene Therapy Approach
Published research alert: Titin splicing regulates cardiotoxicity associated with Calpain-3 gene therapy for LGMD2A/R1 Coalition to Cure Calpain 3 (C3) is pleased to announce the publication of research undertaken by Dr. Isabelle Richard, Head of the Progressive Dystrophy Laboratory, Généthon,
Double your donation on Giving Tuesday 2019
A “C3 Champion” has made a commitment to match every dollar donated on Giving Tuesday, up to $25,000. Your contribution today to support scientific research for those families impacted by the muscle-wasting disease LGMD2A/R1 (a form of calpainopathy)
English
አማርኛ
العربية
简体中文
繁體中文
Dansk
Nederlands
Français
Deutsch
עִבְרִית
हिन्दी
Italiano
日本語
ភាសាខ្មែរ
한국어
كوردی
मराठी
Norsk bokmål
Polski
Português
ਪੰਜਾਬੀ
Русский
Español
Svenska
தமிழ்
తెలుగు
Türkçe